Biocon’s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach
BENGALURU, India, Sept. 22, 2026 /PRNewswire/ — Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE: 532523) (NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the
